For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.


Amgen - Recent Press Releases
RSS Feeds RSS
DateTitle 
12/17/14Amgen Announces 30 Percent Increase In 2015 First Quarter DividendPrinter Friendly Version
12/11/14Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque PsoriasisPrinter Friendly Version
12/08/14Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaPrinter Friendly Version
12/08/14New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced MelanomaPrinter Friendly Version
12/08/14FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate TherapyPrinter Friendly Version
12/06/14Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual DiseasePrinter Friendly Version
12/06/14Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple MyelomaPrinter Friendly Version
12/03/14Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And ExpositionPrinter Friendly Version
12/03/14Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And ResourcesPrinter Friendly Version
12/03/14FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaPrinter Friendly Version